Johnson & Johnson (JNJ) Financial Statements

Johnson & Johnson's financial quality is strong, as assessed against the framework's Section 2 indicators. The company exhibits high profitability with a 28.5% profit margin and a 32.9% Return on Equity (ROE), which far exceeds the 15-20% high-quality threshold for ROIC/ROE. The balance sheet is healthy with a moderate Debt/Equity ratio of 0.59, indicating manageable leverage and financial flexibility. Revenue growth of 9.1% YoY is consistent, though it falls into the mid-single-digit to low-double-digit range rather than the high-growth category. A key point for value investors is the Free Cash Flow (FCF) generation. The FCF Yield of 3.4% is positive and provides a solid base for dividends and buybacks, but it does not meet the framework's 'high' threshold of >10-15% FCF margin on its own merit, suggesting cash conversion is adequate but not exceptional. Regarding growth assessment from Section 3, the 9.1% revenue growth is a sustainable trajectory for a mature healthcare giant, but it is not accelerating nor above the 20% benchmark used for high-growth companies. Growth is likely driven by its entrenched market positions and product portfolio rather than explosive new drivers. Overall, J&J's financial picture is one of a high-quality, stable, and profitable enterprise with a clean balance sheet, but with a mature growth profile and cash flow generation that, while strong, may not be considered explosive relative to some growth-focused value frameworks. Analysis based on data as of 2024-05-15.